$NRXP Income Statement | Understand Stock

$NRXP

$2.69 +$0.14 (5.49%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Net patient service revenue
Cost of patient services
Research and development
General and administrative
Reimbursement of expenses from Relief Therapeutics
Selling, general and administrative
Depreciation and amortization
Settlement expense (income)
Total operating expenses
Loss from operations
Change in fair value of convertible note payable
Change in fair value of earnout cash liability
Interest income
Interest expense
Change in fair value of convertible notes payable
Change in fair value of warrant liabilities
Loss on issuance of Registered Direct Offering
Loss on Consideration Shares and Warrants
Convertible note default penalty
Loss on convertible note conversions
Loss from equity method investments
Gain on exercise of warrants
Total other expense, net
Net loss
Deemed dividend - Earnout Shares
Change in fair value of convertible note attributed to credit risk
Deemed dividend - warrants
Net loss attributable to common stockholders
Net loss per share:
Basic and diluted (in dollars per share)
Basic

Weighted average Common Stock outstanding:
Basic and diluted (in shares)

Comments